migraine headaches. migraine
Conditions
Interventions
Intervention 1: each patient is given 1000 IU of oral vitamin D3 daily for 11 weeks. Intervention 2: each patient is given 1000 IU of oral placebo daily for 11 weeks.
Treatment - Drugs
Placebo
each patient is given 1000 IU of oral vitamin D3 daily for 11 weeks.
each patient is given 1000 IU of oral placebo daily for 11 weeks
Sponsors
Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: inclusion criteria: patients with a diagnosis of migraine headache with no history of underlying diseases such as hyperparathyroidism; cardiac diseases; renal impairment; renal stone; normal or lower serum vitamin D level; no drug history of those interacting with serum vitamin D level exclusion criteria:increasing in serum vitamin D levels over than normal.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of migraine headaches. Timepoint: before intervention, 3months after the initial intervention. Method of measurement: standard questionnarie.;Severity of migraine headaches. Timepoint: before intervention, 3months after initial intervention. Method of measurement: Visual Analouge Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Increasing in serum vitamin D level more than normal level. Timepoint: before intervention,1.5 month after the initial intervention. Method of measurement: serum vitamin D level in blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyedeh Maryam Hashemi
Semnan University of Medical Sciences
Outcome results
None listed